AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by stock analysts at Liberum Capital in a research report issued to clients and investors on Wednesday, August 7th, ThisIsMoney.Co.Uk reports.
Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 25th. Citigroup reissued a “buy” rating and issued a GBX 7,000 ($91.47) price target on shares of AstraZeneca in a research report on Monday, May 13th. Kepler Capital Markets set a GBX 6,470 ($84.54) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Monday, May 13th. Finally, UBS Group reiterated a “sell” rating and set a GBX 5,400 ($70.56) price target on shares of AstraZeneca in a research note on Thursday, July 25th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of GBX 6,688.24 ($87.39).
AstraZeneca stock opened at GBX 7,299 ($95.37) on Wednesday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The stock has a market cap of $94.85 billion and a price-to-earnings ratio of 42.63. The firm has a 50 day simple moving average of GBX 6,755.80 and a 200-day simple moving average of GBX 6,227.49. AstraZeneca has a 1-year low of GBX 5,312 ($69.41) and a 1-year high of GBX 7,349.30 ($96.03).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Stop Order
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.